In evolutionary terms, GH and intracellular STAT 5 signaling is a very old regulatory system.
Whereas insulin dominates periprandially, GH may be viewed as the primary anabolic …

Dysregulated growth hormone (GH) hypersecretion is usually caused by a GH-secreting
pituitary adenoma and leads to acromegaly—a disorder of disproportionate skeletal, tissue …

This review focuses on the systemic complications of acromegaly. Mortality in this disease is
increased mostly because of cardiovascular and respiratory diseases, although currently …

Acromegaly was defined as a syndrome by Pierre Marie in 1885, but in the form of either
acromegaly or acrogigantism has probably been a disorder of antiquity [1, 2]. It is one of the …

To analyze the long term outcome after multimodality therapy for acromegaly, a retrospective
review was performed on 162 patients who underwent transsphenoidal surgery at …

Acromegaly is caused by excess growth hormone (GH) secretion emanating from a
somatotroph adenoma. High GH and Insulin-like growth factor-1 (IGF-1) levels lead to acral …

Cabergoline is a new, long acting, dopamine agonist that is more effective and better
tolerated than bromocriptine in patients with hyperprolactinemia. Because dopamine …

Treatment of acromegaly has long been recognized as necessary to relieve symptoms, halt
progression of deformities, and decompress the sella turcica. More recently, treatment …

Object. The results of surgical therapy for acromegaly were assessed using carefully
conducted endocrinological testing in 115 patients who underwent transsphenoidal surgery …

Objective To evaluate the efficacy, safety and tolerability of octreotide LAR®(long‐acting
repeatable octreotide) in the primary therapy of acromegaly. Design and patients Ninety …